Results 121 to 130 of about 25,204 (165)

Role of ctDNA in Breast Cancer [PDF]

Cancers, 2022
Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment selection.
Eudald Felip, Mireia Margeli Vila
exaly   +7 more sources

The Role of ctDNA in Gastric Cancer

Cancers, 2022
Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural
Naureen Starling
exaly   +4 more sources

ctDNA as a cancer biomarker: A broad overview

Critical Reviews in Oncology/Hematology, 2020
Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been
Valéria Pereira Ferrer
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Chasing ctDNA in Patients With Sarcoma

American Society of Clinical Oncology Educational Book, 2020
Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Catherine C, Coombs, Tony, Dickherber, Brian D, Crompton   +2 more
openaire   +2 more sources

Methods for Measuring ctDNA in Lymphomas

2018
Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide, Condoluci, Adalgisa, Spina, Valeria, Gaidano, Gianluca   +3 more
openaire   +5 more sources

The Landscape of ctDNA in Appendiceal Adenocarcinoma

Clinical Cancer Research
Abstract Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors.
Michael G. White, Mohammad A. Zeineddine, Eleanor A. Fallon, Fadl A. Zeineddine, Julia Dansby, Saikat Chowdhury, Nicholas Hornstein, Abdelrahman Yousef, Mahmoud Yousef, Neal Bhutiani, Yue Gu, Bryan Kee, Arvind Dasari, Michael J. Overman, Kanwal Raghav, Scott Kopetz, Abhineet Uppal, Melissa Taggart, Timothy Newhook, Keith Fournier, Beth Helmink, Leylah M. Drusbosky, John Paul Shen   +22 more
openaire   +2 more sources

ctDNA: Moving toward Clinical Utility

Cancer Discovery, 2022
Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire   +2 more sources

Enrichment and Analysis of ctDNA

2019
ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire   +3 more sources

Review ctDNA and Breast Cancer

2019
In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely fundamental research to nearby daily use for treatment selection and drug-resistance assessment. Indeed, technical advances and widespread use of next-generation sequencing or digital PCR allowed for detection of very low amount of tumor DNA in bloodstream.
openaire   +3 more sources

Dynamic Treatment Stratification Using ctDNA

2019
An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana, Vidal, Alvaro, Taus, Clara, Montagut   +2 more
openaire   +2 more sources